Biogenes signs exclusive licensing agreement with IUKL

Tang ( second, right) exchanging MoA with Ideris while being witnessed by Alan Low (far left), Biogenes Chief Operating Officer, Dr Harcharan Singh (centre), Senior Vice President, Technology Solutions, Bioeconomy Corporation and Cheng Kim Sing, Biogenes Chief Financial Officer.

BANGI: Biogenes Technologies Sdn Bhd (Biogenes), a Malaysian-based company in the field of molecular diagnostics and genomics has signed a licensing agreement with Infrastructure University Kuala Lumpur (IUKL) to commercialise Aptamer technology.

Aptamer, a synthetic alternative to antibodies acts as molecular probes to detect and measure desired target molecules in a sample. This innovation is revolutionary and it may change the way the human body is monitored for clinical purposes as well as to check for